02.03. Área de Salud III Lorca

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review

Thu, 01 Jan 2026 00:00:00 GMT

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review Calvo-Río, Vanesa; Secada-Gómez, Carmen; Martín-Gutierrez, Adrián; Retuerto-Guerrero, Miriam; Font, Judit; Casafont-Sole, Ivette; Mayo-Juanatey, Adrián; Alegre-Sancho, Juan-José; Freites, Dalifer; Hormigos, Cristina; Garrido-Puñal, Noemi; González-Arribas, Guillermo; Miguélez-Sánchez, Juan-Roberto; García-Valle, Andrea; Ibáñez, Marta; Lozano-Morillo, Fernando; García-Manzanares, Ángel; Sandoval-Moreno, Sebastián; Cortés-Hernández, Josefina; Palma-Sánchez, Deseada; Lojo, Leticia; Cervantes-Pérez, Evelin-Cecilia; Collado, Paz; Arciniega-Larios, Cristina; Sala-Icardo, Luis; Labrador-Sánchez, Eztizen; Peralta-Gines, Cilia; Urionaguena-Onaindia, Irati; Plaza-Aulestia, Nahia; Medina-Malone, Miguel; Rosas-Gómez-de-Salazar, José; Corteguera, Montserrat; Cebrian-Mendez, Laura; Anton-Pages, Fred-Antonio; Lamua-Riazuelo, José-Ramón; Fábregas-Canales, María-Dolores; Alados-Hernández, María-José; Garijo-Bufort, Marta; Pamies, Anna; Sarabia-De-Ardanaz, Luis; Aguirre-del-Pino, Rodrigo; Cabezas-Lefler, José-Ángel; Seijas-López, Alvaro; Carrasco-Cubero, María-del-Carmen; López-Ceron-Cofino, Ana; Ortiz-Santamaria, Vera; Laino-Pineiro, María; Ordas-Calvo, Carmen; Arconada-López, Celia; Urruticoechea-Arana, Ana; García-Magallon, Blanca; Acosta-Alfaro, Ana-Valeria; Leal-Rodríguez, Samuel; Salido-Olivares, Marina; Lavilla-Villar, Patricia; Brandy-García, Anahy-M; Ros-Vilamajo, Inmaculada; García-Martos, Álvaro; Magallares-López, Berta-Paula; Sada-Urmeneta, Guillen; Córdoba-Martin, Cristina; Riera, Elena; Bejerano, Carmen; Castañeeda, Santos; Blanco, Ricardo BACKGROUND: Anifrolumab is approved for adults with moderate-to-severe active systemic lupus erythematosus (SLE) based on Randomised clinical trials (RCTs). While randomised pivotal RCTs have demonstrated their efficacy and safety, real-world evidence (RWE) remains limited. OBJECTIVES: To describe the clinical characteristics, effectiveness and safety of anifrolumab in clinical practice and to assess findings from published observational studies. METHODS: Multicentre study of patients with SLE classified according to EULAR/American College of Rheumatology (ACR) 2019. Data were collected from medical records up to 30 April 2025. Variables included demographic characteristics, clinical and serological features, prior and concomitant therapies, disease activity indices including the SLE Disease Activity Index 2000 (SLEDAI-2K), SLE Disease Activity Score (SLE-DAS) and Physician Global Assessment (PGA), damage and disease control measures including the Systemic Lupus International Collaborating Clinics/ACR Damage Index, Lupus Low Disease Activity State (LLDAS) and Definitions of Remission in SLE (DORIS) remission and the association with adverse events (AEs). A review of published observational studies was also conducted. RESULTS: We included 206 patients (183 women; mean age 44.6±12.6 years) from 54 Spanish centres. The most common indications for anifrolumab were cutaneous (61.7%), musculoskeletal (48.5%) and haematological (27.2%).A rapid and sustained improvement was observed in disease activity (SLEDAI-2K, SLE-DAS, PGA), LLDAS, DORIS remission, serological markers (anti-double-stranded DNA, C3/C4) and corticosteroid tapering. Organ damage remained stable. After a mean follow-up of 7.5±5.3 months, the most frequent AEs were herpes zoster (n=?5), respiratory infections (n=?6) and headache (n=?3). Twenty patients discontinued treatment. These results were consistent with published observational studies. CONCLUSION: In this large RWE cohort, anifrolumab demonstrated early and sustained clinical benefit, a favourable safety profile and a significant corticosteroid-sparing effect. These findings reinforce the evidence from CT and support the incorporation of anifrolumab into routine care for patients with SLE.

Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023)

Tue, 17 Mar 2026 00:00:00 GMT

Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023) Berenguer, Juan; Fanciulli, Chiara; Arcos, María-M; Vivancos, María-Jesús; Domingo, Pere; Hernando, Asunción; Barrado, Julia; Ryan, Pablo; Navarro, Jordi; Palacios, Rosario; Morano, Luis-E; Iribarren, José-A; Martínez, Rosa; Galindo, María-J; de-Los-Santos, Ignacio; López-Cruz, Ian; Rivero, Antonio; Pérez-Latorre, Leire; Giner, Livia; Fariñas, María-C; García, Coral; Montero-Alonso, Marta; Ferrero, Óscar-L; Villoslada, Aroa; Soler-González, Josefa-F; Sanz, José; Rodríguez, Sergio; Losa, Juan-E; Bernal-Morell, Enrique; Veloso, Sergio; Pérez-Martínez, Laura; Mateos, Fernando; Arbonés, Laia; Franch, Raquel; Corps, Diana; Martín, Cristina; Alonso-García, Gerardo; Clavero-Olmos, Marta; Silvariño, Rafael; Teira, Ramón; Belinchón, Olga; de-Miguel, Marta; Jarrín, Inmaculada; González-García, Juan BACKGROUND: Hepatitis C virus (HCV) has significantly impacted people with human immunodeficiency virus (HIV). Harm reduction programs, changing transmission patterns, and direct-acting antivirals (DAAs) have profoundly altered HIV/HCV coinfection trends. This study evaluates HCV prevalence among people with HIV in Spain over 2 decades. METHODS: We conducted 9 cross-sectional studies (2002-2023) in 39-43 centers. Sampled individuals were randomly sampled from people with HIV actively followed up at these centers, with proportional allocation. Main outcomes included the prevalence of anti-HCV antibody and active HCV infection (HCV RNA--positive result). RESULTS: The reference population ranged from 31 800 to 47 006, with sample sizes of 1260-1867. HIV transmission patterns shifted from 2002 to 2023, with injection drug use decreasing from 55% to 21% and the proportion of men who have sex with men increasing from 17% to 46%. HCV seroprevalence fell from 60.8% to 27.4%, and active infection from 46.3% to 0.9%. In the DAA era (2015-2023), active HCV infection dropped by 100% in heterosexuals, 94% in people who inject drugs, and 71% in men who have sex with men. Treatment uptake increased from 23% in 2002 to 99% by 2023 with all-oral DAAs. The prevalence of cirrhosis among active HCV cases peaked at 23.1% in 2015 but fell to 0% by 2021. Among those achieving sustained virologic response, cirrhosis prevalence was 20.4% in 2023. CONCLUSIONS: HIV/HCV coinfection has drastically declined in Spain, with active HCV infection prevalence <1% since 2021. DAAs were pivotal in this achievement. However, cirrhosis remains a concern among those with sustained virologic response. Ongoing surveillance and prevention efforts are essential to sustain these gains and address residual risks.

Safety and Effectiveness of Subcutaneous Immunotherapy with a Glutaraldehyde-Polymerized Mite Allergen Extract in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Dermatophagoides

Fri, 23 Jan 2026 00:00:00 GMT

Safety and Effectiveness of Subcutaneous Immunotherapy with a Glutaraldehyde-Polymerized Mite Allergen Extract in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Dermatophagoides Verdeguer-Segarra, Olalla; Almeida-Sánchez, Zulay; Quarta, Silvia; Funes-Vera, Emilio; González-Jiménez, Oscar-M; Hernández-Santana, Guacimara; Herrero-Lifona, Leticia; López-González, Paula; Martínez-Gomariz, Montserrat; López-Cauce, Beatriz; Gómez-Cardeñosa, Aida BACKGROUND/OBJECTIVES: The aim of this study was to evaluate the tolerability and effectiveness of subcutaneous immunotherapy (SCIT) in allergic adults and children treated with a polymerized-glutaraldehyde undiluted mixture of house dust mites (HDMs) under routine clinical practice. METHODS: This was an observational, ambispective, controlled, real-world, multicenter study including patients ? 5 years with allergic rhinitis (AR), due to Dermatophagoides sensitization. Patients who started AIT with a D. pteronyssinus/D. farinae extract and those who continued symptomatic treatment were included in the treatment (DP&DF) and untreated (UT) groups, respectively. We evaluated adverse reactions (ARs) and changes in effectiveness variables through changes in symptoms, disease control, medication use, and patient- and investigator-reported outcomes. RESULTS: We included 130 patients in the DP&DF group, and 90 (69.2%) adults, 23 adolescents (17.7%), 17 (13.1%) children, and 94 patients in the UT group. Patients received treatment for a mean (SD) of 9.01 (3.1) months at the time of evaluation. Seven (5.4%) patients, all adults, reported eight ARs, five local and three systemic (mean rate of 0.62 ARs per 100 injections); all recovered, and epinephrine was not required. The proportion of patients reporting no rhinitis symptoms at follow-up significantly increased (+13.6%; p < 0.001). Rhinitis frequency, intensity, and control significantly improved overall and in specific age groups. Similarly, the proportion of patients reporting no asthma symptoms at follow-up significantly increased (+29.0%; p < 0.001). The use of all symptomatic medications significantly decreased, while the UT group showed no significant changes, except for worsened asthma classification and control in specific age groups. Both investigators and patients perceived a marked improvement in symptoms and medication use, with high satisfaction scores reported on the visual analogue scale. CONCLUSIONS: A subcutaneous allergen extract with a mixture of HDMs is safe and effective for allergic rhinitis and asthma in adults and children in the real-world setting.

Acceso a vacunación no financiada y factores socioeconómicos asociados en una cohorte de lactantes de un área sanitaria de la Región de Murcia

Tue, 19 Aug 2025 00:00:00 GMT

Acceso a vacunación no financiada y factores socioeconómicos asociados en una cohorte de lactantes de un área sanitaria de la Región de Murcia Molina-Salas, Yolanda; Romera-Guirado, Francisco-José; Sánchez-Marin, María-del-Carmen; Navarro-Guerrero, Rosario; Romera-Guirado, María-Jesús; Pérez-Martin, Jaime-Jesús